Opportunity Information: Apply for PA 14 058
Apply for PA 14 058
- The National Institutes of Health in the food and nutrition health sector is offering a public funding opportunity titled "Small Business Innovation Research (SBIR) to Develop New Diagnostic, Monitoring and Therapeutics Technologies for the Complications of Type 1 Diabetes (T1D) (SBIR (R43/R44))" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research.
- This funding opportunity was created on Jan 3, 2014 and posted on Jan 3, 2014.
- Applicants must submit their applications by Jan 7, 2017. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Small businesses.
- Other Eligible Applicants include the following Non domestic (non U.S.) Entities (Foreign Institutions) are not eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The funding opportunity PA 14 058 is a National Institutes of Health (NIH) Small Business Innovation Research (SBIR) grant announcement focused on pushing forward new technologies that can improve how the complications of Type 1 Diabetes (T1D) are detected, tracked, and treated. The core idea behind the program is straightforward: many of the most serious harms from diabetes do not come only from blood sugar itself, but from the long-term damage diabetes can cause to blood vessels throughout the body. These microvascular and macrovascular complications are major drivers of disability, early death, and high health care costs. NIH is using the SBIR mechanism to encourage small businesses to translate promising scientific and engineering concepts into practical tools that clinicians and patients can actually use.
This opportunity specifically targets innovations for early diagnosis, ongoing monitoring, and therapeutics aimed at diabetic vascular complications. In practical terms, that can include technologies that detect complications sooner than current standards, tools that measure progression more precisely over time, and treatment approaches that can prevent, slow, or reverse complication development. Microvascular complications commonly include diabetic retinopathy (eye disease that can lead to vision loss), diabetic nephropathy (kidney disease that can progress to kidney failure), and diabetic neuropathy (nerve damage that contributes to pain, numbness, foot ulcers, and amputations). Macrovascular complications generally refer to larger blood vessel disease such as atherosclerosis and cardiovascular disease, including heart attack and stroke risk. The announcement emphasizes that these complication areas carry substantial morbidity and mortality, so technologies that improve prediction, detection, management, and outcomes in these domains are central to the program’s intent.
The award mechanism is SBIR under the R43/R44 structure, meaning it is designed for U.S. small business concerns and is typically phased to support both early feasibility work and later-stage development. In general SBIR terms, Phase I (often associated with R43) supports proof-of-concept or feasibility testing to show that the proposed technology can work, while Phase II (often associated with R44) supports more extensive research and development, such as prototype refinement, validation studies, and steps toward commercialization. While the specific budget limits and project durations are not provided in the excerpt you shared, the SBIR framework is explicitly oriented toward commercialization: applicants are expected to have a credible plan for turning the research into a product or service that can reach patients, clinicians, and health systems.
Eligibility is limited to small businesses. The opportunity makes clear that non-U.S. (foreign) institutions are not eligible to apply, and non-U.S. components of U.S. organizations are also not eligible to apply. At the same time, “foreign components” as defined in the NIH Grants Policy Statement may be allowed, which usually means discrete portions of the project could potentially be carried out abroad if they meet NIH requirements and are well-justified, but the applicant organization itself must be an eligible U.S. small business. Importantly, there is no cost sharing or matching requirement, so applicants are not required to contribute non-federal matching funds as a condition of the award.
Administratively, the opportunity is categorized as a discretionary grant program with the funding instrument type listed as “Grant,” and it falls under the NIH umbrella with the CFDA listing 93.847, which corresponds to Diabetes, Digestive, and Kidney Diseases Extramural Research. The posting date is January 3, 2014, and the original and final closing date listed is January 7, 2017, with an archive date of February 7, 2017. That means the specific announcement as written is no longer open for new submissions, but it remains useful as a reference for the types of projects NIH has sought to support in this area and for understanding how NIH frames innovation priorities around T1D complication technologies.
For applicants and interested parties who want to review the full announcement details, NIH provided an official link to the program announcement page at http://grants.nih.gov/grants/guide/pa-files/PA-14-058.html (spacing in the source text appears to be formatting-related, but the NIH PA file page is the authoritative location). For technical issues accessing the announcement, the listed point of contact is the NIH Office of Extramural Research (OER) Webmaster at FBOWebmaster@OD.NIH.GOV, which is intended for help with accessing the announcement electronically or resolving linking problems.
Overall, the purpose of PA 14 058 is to leverage the speed and product-focus of small businesses to create next-generation diagnostics, monitoring tools, and therapeutic technologies that meaningfully reduce the burden of vascular complications in Type 1 Diabetes. The emphasis is not just on scientific novelty, but on innovation that can translate into real-world impact by improving early detection, tracking disease progression more effectively, and enabling better interventions to prevent severe outcomes and reduce health system costs.
FAQs: NIH SBIR PA-14-058 (Type 1 Diabetes Vascular Complications Technologies)
What is PA-14-058?
PA-14-058 is a National Institutes of Health (NIH) Small Business Innovation Research (SBIR) funding opportunity focused on advancing new technologies that improve the detection, monitoring, and treatment of vascular complications associated with Type 1 Diabetes (T1D).
What is the main goal of this funding opportunity?
The goal is to support small businesses in translating promising scientific and engineering concepts into practical tools that clinicians and patients can use to reduce the burden of T1D vascular complications, including earlier diagnosis, better tracking of progression, and improved therapeutic approaches.
Why is NIH emphasizing vascular complications in Type 1 Diabetes?
The announcement highlights that many serious harms from diabetes stem from long-term damage to blood vessels throughout the body. These microvascular and macrovascular complications are major drivers of disability, early death, and high health care costs.
What types of innovations does PA-14-058 encourage?
The opportunity specifically targets technologies for early diagnosis, ongoing monitoring, and therapeutics aimed at diabetic vascular complications. This can include tools that detect complications sooner than current standards, measure progression more precisely over time, or prevent, slow, or reverse the development of complications.
Which complications are considered microvascular complications in this announcement?
Microvascular complications cited include:
- Diabetic retinopathy (eye disease that can lead to vision loss)
- Diabetic nephropathy (kidney disease that can progress to kidney failure)
- Diabetic neuropathy (nerve damage associated with pain, numbness, foot ulcers, and amputations)
Which complications are considered macrovascular complications in this announcement?
Macrovascular complications generally refer to large blood vessel disease, including atherosclerosis and cardiovascular disease, with impacts such as increased risk of heart attack and stroke.
What award mechanism is used for PA-14-058?
The mechanism is SBIR under the R43/R44 structure, which is typically phased to support early feasibility work and later-stage development.
What is the difference between SBIR Phase I and Phase II as described here?
In general SBIR terms reflected in the announcement:
- Phase I (often associated with R43) supports proof-of-concept or feasibility testing to demonstrate that the proposed technology can work.
- Phase II (often associated with R44) supports more extensive research and development, such as prototype refinement, validation studies, and steps toward commercialization.
Is commercialization part of the program intent?
Yes. The SBIR framework is explicitly oriented toward commercialization, and applicants are expected to present a credible plan for turning the research into a product or service that can reach patients, clinicians, and health systems.
Who is eligible to apply?
Eligibility is limited to U.S. small business concerns. The announcement states that non-U.S. (foreign) institutions are not eligible to apply.
Are non-U.S. components of U.S. organizations eligible?
No. The opportunity specifies that non-U.S. components of U.S. organizations are not eligible to apply.
Are any foreign activities allowed at all under this opportunity?
Potentially, yes. The announcement notes that "foreign components" (as defined in the NIH Grants Policy Statement) may be allowed, meaning discrete parts of the project could potentially be carried out abroad if they meet NIH requirements and are well-justified. However, the applicant organization must still be an eligible U.S. small business.
Is cost sharing or matching required?
No. The opportunity indicates there is no cost sharing or matching requirement, so applicants are not required to contribute non-federal matching funds as a condition of the award.
What type of funding instrument is this?
The funding instrument type is listed as a "Grant," and it is categorized as a discretionary grant program.
Which agency and program area does this opportunity fall under?
This opportunity is under the NIH umbrella and is associated with CFDA 93.847, described as Diabetes, Digestive, and Kidney Diseases Extramural Research.
When was PA-14-058 posted, and is it still open?
The posting date is January 3, 2014. The original and final closing date listed is January 7, 2017, with an archive date of February 7, 2017. Based on these dates, the specific announcement as written is no longer open for new submissions.
If it is archived, why might PA-14-058 still matter?
Even though it is no longer open, it can still serve as a reference for the kinds of projects NIH has sought to support in T1D complication technologies and for understanding NIH priorities around innovation for detecting, tracking, and treating diabetic vascular complications.
Where can applicants find the official NIH program announcement page?
The official announcement page is listed as: http://grants.nih.gov/grants/guide/pa-files/PA-14-058.html
Who should be contacted for technical issues accessing the announcement?
For technical issues accessing the announcement electronically or resolving linking problems, the contact listed is the NIH Office of Extramural Research (OER) Webmaster at FBOWebmaster@OD.NIH.GOV.
Does the provided information include specific budget limits or project durations?
No. The excerpt indicates that specific budget limits and project durations are not provided in the information shared.
What kinds of outcomes is NIH trying to influence with this program?
The announcement emphasizes real-world impact, including improving early detection, enabling better tracking of disease progression, supporting better interventions to prevent severe outcomes, and reducing health system costs associated with T1D vascular complications.
Browse more business programs for Business Consultants, Innovation Research Organizations, Business Innovation, Diabetes Research
Browse more opportunities from the same agency: National Institutes of Health
Browse more opportunities from the same category: Food and Nutrition Health
Next opportunity: Intelligence Community Center for Academic Excellence
Previous opportunity: Small Business Technology Transfer Research (STTR) to Develop New Diagnostic, Monitoring and Therapeutics Technologies for the Complications of Type 1 Diabetes (T1D) STTR (R41/R42)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 14 058
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 14 058) also looked into and applied for these:
| Funding Opportunity |
|---|
| Research Using Subjects From Selected Type I Diabetes Clinical Studies (Living Biobank) (DP3) Apply for PAR 14 064 Funding Number: PAR 14 064 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Research Using Biosamples From Selected Type 1 Diabetes Clinical Studies (DP3) Apply for PAR 14 065 Funding Number: PAR 14 065 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Cystic Fibrosis Research and Translation Core Center (P30) Apply for RFA DK 13 007 Funding Number: RFA DK 13 007 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $750,000 |
| Systems for Health Apply for RFA 641 14 00002 Funding Number: RFA 641 14 00002 Agency: Ghana USAID Accra Category: Food and Nutrition Health Funding Amount: $68,000,000 |
| Limited Competition for the Continuation of the Diabetes Prevention Program Outcomes Study (DPPOS) (U01) Apply for RFA DK 14 501 Funding Number: RFA DK 14 501 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $400,000 |
| Limited Competition Continuation of the Type 2 Diabetes in Adolescents and Youth (TODAY) Study (U01) Apply for RFA DK 14 502 Funding Number: RFA DK 14 502 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $10,000,000 |
| Accelerating Medicines Partnership (AMP) in Type 2 Diabetes (U01) Apply for RFA DK 14 003 Funding Number: RFA DK 14 003 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $300,000 |
| Limited Competition for the Data Coordinating Center of Accelerating Medicines Partnership (AMP) in Type 2 Diabetes (U01) Apply for RFA DK 14 503 Funding Number: RFA DK 14 503 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $2,500,000 |
| Reagents for Glucagon and Incretin Research (R41/R42) Apply for PA 14 204 Funding Number: PA 14 204 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Reagents for Glucagon and Incretin Research (R43/R44) Apply for RFA DK 14 008 Funding Number: RFA DK 14 008 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Diabetes Impact Award Closed Loop Technologies Clinical, Physiological and Behavioral Approaches to Improve Type 1 Diabetes Outcomes (DP3) Apply for RFA DK 14 014 Funding Number: RFA DK 14 014 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Diabetes Impact Award Closed Loop Technologies Development and Integration of Novel Components for an Automated Artificial Pancreas System (DP3) Apply for RFA DK 14 015 Funding Number: RFA DK 14 015 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Nutrition Obesity Research Centers (NORCs) (P30) Apply for RFA DK 14 002 Funding Number: RFA DK 14 002 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $750,000 |
| Silvio O. Conte Digestive Diseases Research Core Centers (P30) Apply for RFA DK 14 012 Funding Number: RFA DK 14 012 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $750,000 |
| Increasing the Quality and Efficiency of Clinical Trials (R18) Apply for RFA FD 14 017 Funding Number: RFA FD 14 017 Agency: Food Drug Administration Category: Food and Nutrition Health Funding Amount: $7,500,000 |
| U.S. India Bilateral Collaborative Research Partnerships (CRP) on Diabetes Research (R21) Apply for RFA DK 14 006 Funding Number: RFA DK 14 006 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $275,000 |
| Polycystic Kidney Disease (PKD) Research and Translation Core Centers (P30) Apply for RFA DK 14 013 Funding Number: RFA DK 14 013 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $750,000 |
| Research Using Biosamples From Selected Type 1 Diabetes Clinical Studies (DP3) Apply for PAR 14 257 Funding Number: PAR 14 257 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $4,000,000 |
| Research Using Subjects From Selected Type 1 Diabetes Clinical Studies (Living Biobank) (DP3) Apply for PAR 14 258 Funding Number: PAR 14 258 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $7,000,000 |
| Chronic Kidney Disease Biomarkers Consortium (CKD BioCon) (U01) Apply for RFA DK 14 011 Funding Number: RFA DK 14 011 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $450,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 14 058", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.